Form 4: Athira Pharma Executive Acquires Stock Options and Restricted Stock Units

Robert Renninger, SVP of Finance and Accounting at Athira Pharma, reports the acquisition of stock options and restricted stock units.

Summary

• Robert Renninger, SVP of Finance and Accounting at Athira Pharma, filed a Form 4 detailing changes in beneficial ownership.
• On March 3, 2025, Renninger acquired stock options for 58,500 shares at an exercise price of $0.3762, vesting monthly over 48 months.
• He also acquired stock options for 73,350 shares at an exercise price of $0.3762, with 1/4 vesting on the one-year anniversary and 1/36 vesting monthly thereafter.
• Additionally, Renninger acquired 39,000 restricted stock units (RSUs), each representing one share of Athira Pharma's common stock, vesting 100% on the one-year anniversary of the grant date.
• All vesting is contingent upon Renninger's continued service with Athira Pharma.

Sentiment

Score: 6

Explanation: Neutral sentiment as it's a standard regulatory filing detailing executive compensation. The acquisition of stock options and RSUs could be seen as a slightly positive sign, but it's not a major event.

Positives

• The acquisition of stock options and RSUs by a key executive could be seen as a positive sign, indicating confidence in the company's future performance.

Industry Context

Form 4 filings are standard practice and provide transparency into the transactions of company insiders, allowing investors to track ownership changes and potential alignment of interests.

Comparison to Industry Standards

• Stock option and RSU grants are common forms of executive compensation in the biotechnology industry, used to incentivize performance and align executive interests with shareholder value.
• Vesting schedules, such as the monthly and annual vesting described in the document, are typical in such grants.
• Similar compensation structures can be observed at comparable companies like Biogen, Amgen, and Regeneron.

Stakeholder Impact

• The transactions reported in the Form 4 could have a minor impact on shareholders by potentially diluting the value of existing shares upon exercise of the stock options and vesting of the RSUs.

Key Dates